Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivationHerbert Nar, Paul Declerck, Margit Bauer et al.|Journal of Molecular Biology|2000Cited by 95
Characterization and Comparative Evaluation of a Novel PAI-1 InhibitorAnn Gils, Paul Declerck, Jean–Marie Stassen et al.|Thrombosis and Haemostasis|2002Cited by 33
Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's diseaseZhigang Wang, Erwin Dreesen, Bram Verstockt et al.|British Journal of Clinical Pharmacology|2021Cited by 32
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab ConcentrationsNathalie Van den Berghe, Debby Thomas, Ann Gils et al.|Journal of Crohn s and Colitis|2020Cited by 15
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn’s DiseaseNathalie Van den Berghe, Paul Declerck, Bram Verstockt et al.|Clinical Gastroenterology and Hepatology|2021Cited by 7